irinotecan + cisplatin

Irinotecan + cisplatin is a combination chemotherapy regimen used primarily for the treatment of various solid tumors, most notably extensive-stage small cell lung cancer and metastatic thymic carcinoma. Irinotecan is a DNA topoisomerase I inhibitor that, after conversion to its active metabolite SN-38, prevents religation of single-strand DNA breaks during replication and transcription, leading to apoptosis in rapidly dividing cells[2][5][6]. Cisplatin is a platinum-based agent that forms DNA crosslinks (both interstrand and intrastrand), thereby inhibiting DNA synthesis and function, ultimately triggering cell death[8]. This combination has demonstrated efficacy as first-line therapy in several cancers with acceptable toxicity profiles[1][3][4].

Brand names

Camptosar + cisplatin

Other names

cisplatin and irinotecancisplatin plus irinotecanPI regimen